Thus, we propose that upregulation of PDE10A in ovarian cancer will lead to worse patient outcomes due to increased oncogenic signaling that provides cells with growth and survival advantages as well as a tumor microenvironment favorable for cancer progression. Here, PDE10A is linked to neoplasm.